The effect of angiotensin II receptor blockade on an end-stage renal failure model of type 2 diabetes

被引:45
作者
Mizuno, Makoto
Sada, Toshio
Kato, Mikio
Fukushima, Yasuo
Terashima, Hideki
Koike, Hiroyuki
机构
[1] Sankyo Co Ltd, Pharmacol & Mol Biol Res Labs, Pharmacodynam Res Labs, Shinagawa Ku, Tokyo 1408710, Japan
[2] Sankyo Co Ltd, R&D Headquarters, Tokyo 1408710, Japan
关键词
type; 2; diabetes; nephropathy; angiotensin receptor blocker; Zucker diabetic fatty rat; survival;
D O I
10.1097/01.fjc.0000245241.79959.d6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The effect of olmesartan medoxomil (OLM), an angiotensin 11 receptor blocker (ARB), on advanced nephropathy and mortality was evaluated in Zucker Diabetic Fatty (ZDF) rats, a type 2 diabetes model. OLM was administered from 36 weeks of age, when the animals developed advanced proteinuria. OLM effectively suppressed the progression of proteinuria. The ZDF rats started to die at 50 weeks of age, which was accompanied by abrupt increase in blood urea nitrogen, suggesting that the cause of death was renal insufficiency. OLM suppressed increases in blood urea nitrogen and increased the survival rate of the ZDF rats. The histological examination revealed that the renal damage was ameliorated by OLM. The macrophage infiltration and monocyte chemoattractant protein-1 (MCP-1) expression was increased in the glomeruli and tubulointerstitium of the ZDF rat kidneys, and the increase was lessened by OLM. In a separate study, albumin increased MCP-1 release from cultured tubular epithelial cells. These results suggest that protein leakage from the glomeruli stimulates MCP-1 production in tubular cells and that MCP-1 released into the interstitial space induces macrophage infiltration and inflammation. It is conceivable that the beneficial actions of ARB on diabetic nephropathy are, at least in part, due to decrease of proteinuria and the subsequent reduction of inflammatory changes in tubular cells.
引用
收藏
页码:135 / 142
页数:8
相关论文
共 21 条
[1]   RENAL RENIN-ANGIOTENSIN SYSTEM IN DIABETES - FUNCTIONAL, IMMUNOHISTOCHEMICAL, AND MOLECULAR BIOLOGICAL CORRELATIONS [J].
ANDERSON, S ;
JUNG, FF ;
INGELFINGER, JR .
AMERICAN JOURNAL OF PHYSIOLOGY, 1993, 265 (04) :F477-F486
[2]  
[Anonymous], 2005, DIABETES CARE, V28, pS4
[3]   Analysis of metabolic parameters as predictors of risk in the RENAAL study [J].
Appel, GB ;
Radhakrishnan, J ;
Avram, MM ;
DeFronzo, RA ;
Escobar-Jimenez, F ;
Campos, MM ;
Burgess, E ;
Hille, DA ;
Dickson, TZ ;
Shahinfar, S ;
Brenner, BM .
DIABETES CARE, 2003, 26 (05) :1402-1407
[4]   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869
[5]   Peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats [J].
Buckingham, RE ;
Al-Barazanji, KA ;
Toseland, CDN ;
Slaughter, M ;
Connor, SC ;
West, A ;
Bond, B ;
Turner, NC ;
Clapham, JC .
DIABETES, 1998, 47 (08) :1326-1334
[6]   Need for an incentive-based reimbursement policy toward quality care for dialysis patient management [J].
Hidai, H .
KIDNEY INTERNATIONAL, 2000, 58 (01) :363-373
[7]   Long-term blockade of angiotensin AT1 receptors increases survival of obese Zucker rats [J].
Janiak, P ;
Bidouard, JP ;
Cadrouvele, C ;
Poirier, B ;
Gouraud, L ;
Grataloup, Y ;
Pierre, F ;
Bruneval, P ;
O'Connor, SE ;
Herbert, JM .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 534 (1-3) :271-279
[8]  
KOHZUKI M, 1995, J HYPERTENS, V13, P97
[9]   Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes [J].
Lewis, EJ ;
Hunsicker, LG ;
Clarke, WR ;
Berl, T ;
Pohl, MA ;
Lewis, JB ;
Ritz, E ;
Atkins, RC ;
Rohde, R ;
Raz, I .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :851-860
[10]   Renoprotective effects of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes [J].
Mizuno, M ;
Sada, T ;
Kato, M ;
Koike, H .
HYPERTENSION RESEARCH, 2002, 25 (02) :271-278